Scripscan: FDC Ltd
cmp:50
code:531599
Story: FDC makes both formulations and Active Pharmaceutical Ingredients (API) in the pharmaceutical space. Its expertise in ophthalmic and ORS dosage forms has helped it spread its reach across the market. It also has a presence in various therapeutic segments, such as anti-infectives, dermatologicals, respiratory and haematinics.With over 90 per cent of its turnover from the domestic market, FDC is pursuing contract manufacturing opportunities in the regulated and semi-regulated markets for sterile ophthalmic and oral solid dosage forms. The contract manufacturing and clinical market in India is expected to reach $900 million and $1 billion by 2010, respectively, due to the cost advantage India offers. FDC, with its strong presence and R&D expertise, is poised to take advantage of this potential. On the domestic front, the pharma market is expected to grow at a compounded annual growth rate of 16 per cent over 2007-2011.FDC has launched new products and line extensions of its existing products (introduced line extension to its flagship brand ZIFI for treating lower respiratory tract infections). It has also received an approval from the USFDA for its abbreviated new drug application (ANDA), ciprofloxacin ophthalmic solution (antibiotic used for occular surface infections) and timolol maleate ophthalmic solution (used for glaucoma). It has around five more products at an advanced stage of filing.Since January, FDC’s share has been on a steady upmove and is still trading at an attractive valuation of 10 times its forward12 months earnings. This valuation is low when compared to what the larger pharma stocks like Dr Reddy’s Laboratories (16 times) and Sun Pharmaceutical (18 times) command.Invest for steady capital appreciation.
Search This Blog(Over 800 companies covered in the blog).
Archives : Old artciles
Tuesday, September 29, 2009
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
